Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMP-506
- Development stage
- Preclinical
- Lead developer
- Amplifica Holdings Group
- Modality
- Small Molecules
- Administration
- Unknown
01
Overview
AMP-506 is a chemical drug under development by Amplifica Holdings Group for the treatment of androgenetic alopecia (pattern hair loss). The compound is part of Amplifica's pipeline focused on novel, nature-inspired therapies that stimulate dormant hair follicle stem cells and promote natural hair regrowth. While the precise molecular target and mechanism of action have not been publicly disclosed, the company’s approach involves proprietary signaling molecules that activate hair follicles to regrow hair. As of May 2025, AMP-506 remains in preclinical development for skin and musculoskeletal diseases, specifically targeting androgenetic alopecia[1][5].
Beyond the preview
Go deeper on AMP-506.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMP-506.